The Impact of Preoperative 5-alpha Reductase Inhibitors on Functional Outcomes and Health-related Quality of Life Following Radical Prostatectomy - A Propensity Score Matched Longitudinal Study

Overview

Journal World J Urol

Specialty Urology

Date 2024 Jul 22

PMID 39037579

Authors

Thilo Westhofen

Kerstin Frank

Alexander Buchner

Armin Becker

Lennert Eismann

Severin Rodler

Can Aydogdu

Elena Berg

Friedrich Jokisch

Philipp M Kazmierczak

Christian G Stief

Alexander Kretschmer

Affiliations

Soon will be listed here.

Abstract

Objectives: While the impact of treatment with 5-alpha Reductase Inhibitors (5-ARI) on the risk of cancer-related mortality in men with prostate cancer (PC) has been extensively studied, little is known about the impact of preoperative 5-ARI use on patient-reported outcomes (PROs) following radical prostatectomy (RP).

Methods: Within our prospectively maintained institutional database of 5899 patients treated with RP for PC (2008- 2021), 99 patients with preoperative 5-ARI therapy were identified. A 1:4 propensity-score matched analysis of 442 men (n = 90 5-ARI, n = 352 no 5-ARI) was conducted. Primary endpoint was continence recovery using daily pad usage and ICIQ-SF. Health-related quality of life (HRQOL) was assessed using the validated EORTC QLQ-C30 and PR25 questionnaires. Multivariable Cox-regression-models tested the effect of preoperative 5-ARI treatment on continence-recovery (p < 0.05).

Results: Patients were followed up perioperatively, followed by annual assessments up to 60mo postoperatively. Preoperative mean ICIQ-SF score (2.2 vs. 0.9) was significantly higher in the 5-ARI cohort (p = 0.006). 24mo postoperatively, 68.6% (no 5-ARI) vs. 55.7% (5-ARI) had full continence recovery (p = 0.002). Multivariable Cox regression analysis, revealed preoperative 5-ARI treatment as an independent predictor for impaired continence recovery (HR 0.50, 95% CI 0.27-0.94, p = 0.03) In line, general HRQOL was significantly higher for patients without 5-ARI only up to 24mo postoperatively (70.6 vs. 61.2, p = 0.045). There was no significant impact of preoperative 5-ARI treatment on erectile function, biochemical recurrence-free survival and metastasis-free survival.

Conclusions: Pre-RP 5-ARI treatment was associated with impaired continence outcomes starting 24mo postoperatively, suggesting that preoperative 5-ARI treatment can impair the long-term urinary function recovery following RP.

References

McConnell J, Wilson J, George F, Geller J, Pappas F, Stoner E . Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. J Clin Endocrinol Metab. 1992; 74(3):505-8. DOI: 10.1210/jcem.74.3.1371291. View

Bjornebo L, Nordstrom T, Discacciati A, Palsdottir T, Aly M, Gronberg H . Association of 5α-Reductase Inhibitors With Prostate Cancer Mortality. JAMA Oncol. 2022; 8(7):1019-1026. PMC: 9121300. DOI: 10.1001/jamaoncol.2022.1501. View

Finelli A, Komisarenko M, Martin L, Timilshina N, Jain K, Morris J . Long-term use of 5-alpha-reductase inhibitors is safe and effective in men on active surveillance for prostate cancer. Prostate Cancer Prostatic Dis. 2020; 24(1):69-76. DOI: 10.1038/s41391-020-0218-2. View

Kearns J, Faino A, Schenk J, Newcomb L, Brooks J, Carroll P . Continued 5α-Reductase Inhibitor Use after Prostate Cancer Diagnosis and the Risk of Reclassification and Adverse Pathological Outcomes in the PASS. J Urol. 2018; 201(1):106-111. PMC: 10958899. DOI: 10.1016/j.juro.2018.07.065. View

Kretschmer A, Mandel P, Buchner A, Stief C, Tilki D . Surgical learning curve for open radical prostatectomy: Is there an end to the learning curve?. World J Urol. 2015; 33(11):1721-7. DOI: 10.1007/s00345-015-1540-5. View

Ming K, Rosenbaum P . Substantial gains in bias reduction from matching with a variable number of controls. Biometrics. 2000; 56(1):118-24. DOI: 10.1111/j.0006-341x.2000.00118.x. View

Avery K, Donovan J, Peters T, Shaw C, Gotoh M, Abrams P . ICIQ: a brief and robust measure for evaluating the symptoms and impact of urinary incontinence. Neurourol Urodyn. 2004; 23(4):322-30. DOI: 10.1002/nau.20041. View

Aaronson N, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez N . The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993; 85(5):365-76. DOI: 10.1093/jnci/85.5.365. View

Snyder C, Blackford A, Okuyama T, Akechi T, Yamashita H, Toyama T . Using the EORTC-QLQ-C30 in clinical practice for patient management: identifying scores requiring a clinician's attention. Qual Life Res. 2013; 22(10):2685-91. PMC: 3843980. DOI: 10.1007/s11136-013-0387-8. View

10.

Rhoden E, Teloken C, Sogari P, Vargas Souto C . The use of the simplified International Index of Erectile Function (IIEF-5) as a diagnostic tool to study the prevalence of erectile dysfunction. Int J Impot Res. 2002; 14(4):245-50. DOI: 10.1038/sj.ijir.3900859. View

11.

Assel M, Sjoberg D, Elders A, Wang X, Huo D, Botchway A . Guidelines for Reporting of Statistics for Clinical Research in Urology. J Urol. 2019; 201(3):595-604. PMC: 6600813. DOI: 10.1097/JU.0000000000000001. View

12.

Lardas M, Grivas N, Debray T, Zattoni F, Berridge C, Cumberbatch M . Patient- and Tumour-related Prognostic Factors for Urinary Incontinence After Radical Prostatectomy for Nonmetastatic Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol Focus. 2021; 8(3):674-689. DOI: 10.1016/j.euf.2021.04.020. View

13.

Mottet N, van den Bergh R, Briers E, Van den Broeck T, Cumberbatch M, De Santis M . EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2020; 79(2):243-262. DOI: 10.1016/j.eururo.2020.09.042. View

14.

Westhofen T, Buchner A, Schlenker B, Becker A, Chaloupka M, Bischoff R . A matter of size? Health-related quality of life after radical prostatectomy for patients with giant prostates. Prostate. 2021; 81(8):443-451. DOI: 10.1002/pros.24124. View

15.

Herbst K, Bhasin S . Testosterone action on skeletal muscle. Curr Opin Clin Nutr Metab Care. 2004; 7(3):271-7. DOI: 10.1097/00075197-200405000-00006. View

16.

Rehder P, Staudacher N, Schachtner J, Berger M, Schillfahrt F, Hauser V . Hypothesis That Urethral Bulb (Corpus Spongiosum) Plays an Active Role in Male Urinary Continence. Adv Urol. 2016; 2016:6054730. PMC: 4752977. DOI: 10.1155/2016/6054730. View

17.

Rizk J, Sahu R, Duteil D . An overview on androgen-mediated actions in skeletal muscle and adipose tissue. Steroids. 2023; 199:109306. DOI: 10.1016/j.steroids.2023.109306. View

18.

Paula Domino M, Vertosick E, Vickers A, Eastham J, Sandhu J . The Association Between Low Preoperative Serum Testosterone and Post-radical Prostatectomy Urinary Function. Urology. 2023; 180:190-193. PMC: 11457297. DOI: 10.1016/j.urology.2023.07.016. View

19.

Traish A, Krakowsky Y, Doros G, Morgentaler A . Do 5α-Reductase Inhibitors Raise Circulating Serum Testosterone Levels? A Comprehensive Review and Meta-Analysis to Explaining Paradoxical Results. Sex Med Rev. 2018; 7(1):95-114. DOI: 10.1016/j.sxmr.2018.06.002. View

20.

Yarrow J, McCoy S, Borst S . Intracrine and myotrophic roles of 5α-reductase and androgens: a review. Med Sci Sports Exerc. 2011; 44(5):818-26. PMC: 8382298. DOI: 10.1249/MSS.0b013e31823bfcbf. View